scholarly article | Q13442814 |
P2093 | author name string | S. Pierce | |
E. Anaissie | |||
M. J. Keating | |||
M. Beran | |||
S. O'Brien | |||
L. Robertson | |||
E. Estey | |||
H. M. Kantarjian | |||
P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
Cancer chemotherapy reports | Q27710278 | ||
Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy | Q34560161 | ||
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer | Q40746556 | ||
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia | Q40766706 | ||
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium | Q40785644 | ||
Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia | Q40805621 | ||
Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin | Q45229426 | ||
Acceleration of neutrophilic granulocyte recovery after bone-marrow transplantation by administration of recombinant human granulocyte colony-stimulating factor. | Q45996225 | ||
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma | Q46138485 | ||
Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia | Q48300032 | ||
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. | Q54382751 | ||
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples | Q56428666 | ||
Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation | Q63446345 | ||
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease | Q67719984 | ||
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer | Q67989066 | ||
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia | Q68514600 | ||
Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease | Q69386550 | ||
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease | Q69484546 | ||
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression | Q70201925 | ||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | acute lymphocytic leukemia | Q180664 |
lymphocyte | Q715347 | ||
P304 | page(s) | 2950-2955 | |
P577 | publication date | 1993-11-01 | |
1993-11-15 | |||
P1433 | published in | Cancer | Q326041 |
P1476 | title | Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission | |
P478 | volume | 72 |
Q41634907 | A comparative review of colony-stimulating factors |
Q73127004 | Adult acute leukemia |
Q35024453 | Colony-stimulating factors for the management of neutropenia in cancer patients |
Q43599735 | Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia |
Q58414487 | Growth factors in the treatment of acute lymphoblastic leukemia |
Q43909452 | High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia |
Q40631353 | Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. |
Q48263650 | Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. |
Q36405044 | Role of cytokines in the treatment of acute leukemias: a review |
Q35605280 | Surgical wound healing using hemostatic gauze scaffold loaded with nanoparticles containing sustained-release granulocyte colony-stimulating factor |
Q36177546 | Sustained-release G-CSF microspheres using a novel solid-in-oil-in-oil-in-water emulsion method |